Navigation Links
Mega Stock Picks (megastockpicks.com) Initiates Coverage on FDA Approval for POZEN, Inc.(NasdaqGM: POZN) Drug Vimovo with Immediate Buy Recommendation
Date:3/25/2010

Mega Stock Picks (www.megastockpicks.com) gives it's top buy recommendation to Pozen, Inc (NasdaqGM: POZN) upon approval of it's FDA submitted drug, Vimovo.

New York, NY (PRWEB) March 25, 2010 -- Mega Stock Picks, a reputable internet-based free subscriber newsletter, announced today that they are initiating full coverage on pending FDA Approval of Vimovo by POZEN, Inc. (NasdaqGM: POZN). Sign up for Mega Stock Picks free subscriber newsletter at http://www.megastockpicks.com.

Widely known for its successful stock alerts which focus mainly on pharmaceutical and undervalued penny securities, Mega Stock Picks has issued a strong buy alert for POZN with a 6 month price target of 25.00. Mega Stock Picks has given POZN its strongest buy recommendation.

Pozen, Inc (POZN) is currently one of the top performing stocks in the small-to-mid cap biotechnology industry. We believe this company is well diversified and financially sound with current collaborations with GlaxoSmithKline (NYSE: GSK), over $46 million in cash available and potentially more coming in April 2010 from a collaboration and license agreement with AstraZeneca (NYSE: AZN) for the US approval of its pending FDA approved drug, Vimovo.

Vimovo, a combination pill of naproxen (Aleve) and immediate release esomeprazole (Nexium), for arthritis patients (the addition of esomeprazole reduces the risk of stomach ulcers), is up for FDA decision on April 30th, 2010 and Mega Stock Picks believes this exciting new drug will receive a positive response.

Mega Stock Picks has built a reputation on alerting the most successful Pharmaceutical stocks prior to FDA approval such as VNDA, KERX, and CTIC. To sign up for these alerts, please visit http://www.megastockpicks.com.

About POZEN, Inc.
POZEN Inc. engages in the development of pharmaceutical products for the treatment of acute and chronic pain, and other pain-related conditions. The company has a collaboration agreement with GlaxoSmithKline for Treximet, which is used for the acute treatment of migraine attacks with or without aura in adults; and a collaboration and license agreement with AstraZeneca for VIMOVO, a proprietary fixed dose combination of the proton pump inhibitor esomeprazole magnesium with the naproxen in a single tablet for the management of pain and inflammation associated with conditions, such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing non-steroidal anti-inflammatory drug-associated gastric ulcers. It also develops PA32540, a Phase III clinical trial product, which is a combination of a proton pump inhibitor and aspirin for the secondary prevention of cardiovascular disease in patients at risk for gastric ulcers. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.

Megastockpicks.com (”website”) has not been compensated, rather they have initiated their own independent research on Pozen Inc. The website is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. You understand and acknowledge that there is a very high degree of risk involved in trading securities. The website, the authors, the publisher, and all affiliates of website assume no responsibility or liability for your trading and investment results. Factual statements on the website, or in its publications, are made as of the date stated and are subject to change without notice. It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Examples presented on Megastockpicks.com’s website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial adviser and tax adviser to determine the suitability of any investment. Please view full disclaimer at the website.

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3776614.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. American Public Health Champion Receives 2010 Stockholm Water Prize
2. PROLOR Biotech Announces Sale of $24.4 Million of Common Stock
3. StockCross Trades for a Cure: Seventh Annual Trading for a Cure Day Set
4. Tickerspy.com Announces New Stock Index Tracking Chinese Healthcare Stocks
5. Are Stock Market Woes Bad for the Heart?
6. Micromet Announces Pricing of Public Offering of 10 Million Shares of Common Stock
7. Tuba City Regional Health Care Corporation Selects Stockell Healthcare to Deploy Patient Access and Revenue Cycle Management Solution
8. Yongye International to Present at the 22nd Roth OC Growth Stock Conference
9. Smart Balance to Present at Roth Growth Stock Conference
10. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 22nd Annual OC Growth Stock Conference
11. BetterInvesting Magazine Releases May Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mega Stock Picks (megastockpicks.com) Initiates Coverage on FDA Approval for POZEN, Inc.(NasdaqGM: POZN) Drug Vimovo with Immediate Buy Recommendation
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
Breaking Medicine Technology: